M&A Deal Summary

Biolinerx Acquires Agalimmune

On March 23, 2017, Biolinerx acquired life science company Agalimmune for 6M USD

Acquisition Highlights
  • This is Biolinerx’s 1st transaction in the Life Science sector.
  • This is Biolinerx’s largest (disclosed) transaction.
  • This is Biolinerx’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2017-03-23
Target Agalimmune
Sector Life Science
Buyer(s) Biolinerx
Deal Type Add-on Acquisition
Deal Value 6M USD

Target

Agalimmune

London, United Kingdom
Agalimmune Ltd. is a biopharmaceutical company with an innovative anti-cancer immunotherapy pipeline for generating a systemic, adaptive immune response to solid tumors. It was established in 2013 and is headquartered in London, England with laboratories in Sandwich, England and Boston, Massachusetts.

Search 202,196 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biolinerx

Jerusalem, Israel
Category Company
Founded 2003
Sector Healthcare Services
Employees43
DESCRIPTION

Biolinerx Ltd. is a clinical-stage bio-pharmaceutical company based in Jerusalem, Israel, dedicated to identifying, in-licensing and developing promising therapeutic candidates.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal